Comparative Pharmacology
Head-to-head clinical analysis: NICOTINE versus NICOTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICOTINE versus NICOTROL.
NICOTINE vs NICOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
Nicotine is a nicotinic acetylcholine receptor agonist. It binds to and activates nicotinic acetylcholine receptors in the brain, leading to dopamine release and other neurotransmitter effects that mediate nicotine dependence and withdrawal symptoms.
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
Inhalation: 1 cartridge (4 mg) inhaled as needed for craving relief, up to 16 cartridges per day; typical initial dose: 4-8 cartridges per day, with weaning over 12 weeks.
None Documented
None Documented
Clinical Note
moderateNicotine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nicotine resulting in a loss in efficacy."
Clinical Note
moderateTerminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
2 hours (range 1-4 h). Shorter in smokers due to induction of metabolism; prolonged in renal impairment.
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Primarily renal (10-20% unchanged; 80-90% as metabolites, mainly cotinine and nicotine-N'-oxide). Biliary/fecal excretion accounts for <10%.
Category C
Category C
Smoking cessation aid
Smoking cessation aid
Nicotine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Nicotine."